Phase II study of imatinib mesylate and docetaxel in patients with metastatic or recurrent head and neck squamous cell cancer.

Trial Profile

Phase II study of imatinib mesylate and docetaxel in patients with metastatic or recurrent head and neck squamous cell cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Docetaxel; Imatinib
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top